Disposition of 21000 shares by Jack Khattar of Supernus Pharmaceuticals subject to Rule 16b-3

SUPN Stock  USD 37.31  0.74  2.02%   
About 69 percent of all Supernus Pharmaceuticals' investors are curious in acquiring. The analysis of overall sentiment of trading Supernus Pharmaceuticals stock suggests that quite a few investors are confidant at this time. Supernus Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Supernus Pharmaceuticals. Many technical investors use Supernus Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Supernus Pharmaceuticals Director, Officer: President, Ceo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at macroaxis.com
Supernus insider trading alert for disposition of performance share unit by Jack Khattar, Director, Officer: President, Ceo, on 3rd of September 2024. This event was filed by Supernus Pharmaceuticals with SEC on 2024-09-03. Statement of changes in beneficial ownership - SEC Form 4. Jack Khattar currently serves as founder, ceo and president and director of Supernus Pharmaceuticals

Cash Flow Correlation

Supernus Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Supernus Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Supernus Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Supernus Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Supernus Pharmaceuticals Historical Investor Sentiment

Investor biases related to Supernus Pharmaceuticals' public news can be used to forecast risks associated with an investment in Supernus. The trend in average sentiment can be used to explain how an investor holding Supernus can time the market purely based on public headlines and social activities around Supernus Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Supernus Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Supernus Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Supernus Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Supernus Pharmaceuticals.

Supernus Pharmaceuticals Fundamental Analysis

We analyze Supernus Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Supernus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Supernus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Total Debt

Total Debt Comparative Analysis

Supernus Pharmaceuticals is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Supernus Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Supernus Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Supernus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Supernus Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Supernus Pharmaceuticals Related Equities

When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:
Check out Supernus Pharmaceuticals Hype Analysis, Supernus Pharmaceuticals Correlation and Supernus Pharmaceuticals Performance.
To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.99)
Earnings Share
1.07
Revenue Per Share
11.877
Quarterly Revenue Growth
0.142
Return On Assets
0.0289
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.